Status:
ENROLLING_BY_INVITATION
Relationship Between Oral DMT Burden and Adherence in MS
Lead Sponsor:
Monash University
Conditions:
Multiple Sclerosis
Adherence, Medication
Eligibility:
All Genders
18-99 years
Brief Summary
STATURE is a prospective observational six-arm translation multi-site study that will run for approx. 4.5 years. The primary aim is to measure treatment burden and its relationship to medication adher...
Eligibility Criteria
Inclusion
- 18 years or older.
- A confirmed diagnosis of multiple sclerosis.
- Commencement (switching or newly prescribed) of one of the 6 following DMTs within the previous 2-months: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, diroximel fumarate.
- Able to read and write in English.
- Access to an internet connection and computer facilities, required to complete assessments.
Exclusion
- Use of any other DMT than cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, diroximel fumarate.
- Comorbid neurological condition.
- Severe cognitive or psychological dysfunction deemed to interfere with the person's ability to undertake study requirements, as determined by their MS clinic treatment team (neurologist; MS nurse).
Key Trial Info
Start Date :
September 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 11 2026
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT04676204
Start Date
September 25 2020
End Date
July 11 2026
Last Update
August 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Monash University
Melbourne, Victoria, Australia, 3800